

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/678,016	10/02/2000	Keith P. Wilson	VPI/96-03 DIV2	7947
1473	7590 07/06/2006		EXAMINER	
	AVE IP GROUP	ALLEN, MARIANNE P		
ROPES & GRAY LLP 1251 AVENUE OF THE AMERICAS FL C3			ART UNIT	PAPER NUMBER
NEW YORK, NY 10020-1105			1647	

DATE MAILED: 07/06/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
Office Action Summans	09/678,016	WILSON ET AL.					
Office Action Summary	Examiner	Art Unit					
	Marianne P. Allen	1647					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION (6(a). In no event, however, may a reply be timed the same of th	the mailing date of this communication. O (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on 19 Ap	oril 2006.						
	action is non-final.						
· —	,—						
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4)⊠ Claim(s) <u>23,27-34,37,38,40,41,44,47,63 and 72-85</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6)☐ Claim(s) is/are rejected.							
7) Claim(s) 23,27-34,37,38,40,41,44,47,63 and 72	7)⊠ Claim(s) <u>23,27-34,37,38,40,41,44,47,63 and 72-85</u> is/are objected to.						
8) Claim(s) are subject to restriction and/or							
Application Papers							
9) The specification is objected to by the Examine	•						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
12)∐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some * c) ☐ None of:							
2. Certified copies of the priority documents have been received in Application No3. Copies of the certified copies of the priority documents have been received in this National Stage							
		d in this National Stage					
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
See the attached detailed Office action for a list	or the certified copies not receive	a.					
Attachment(s)	🗖	(DTD 440)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Linterview Summary Paper No(s)/Mail Da	,					
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)	5) Notice of Informal P	atent Application (PTO-152)					
Paper No(s)/Mail Date	6) Other:						

DETAILED ACTION

Page 2

Claim Objections

Claim 85 is objected to under 37 CFR 1.75 as being a substantial duplicate of claim 82. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 706.03(k).

Claim 85 does not appear to differ in scope from claim 82 although worded differently.

Both claims require docking a chemical entity to the same IMDPH binding pocket and selecting the chemical entity by the same criteria.

The claims are objected to because of the following informalities.

Claim 23 recites ("IMPDH") in quotation marks and parentheses in lines 5 and 12. See also claims 29, 32, and 72. The claims specifically indicate that this acronym is for inosine monophosphate dehydrogenase.

Claim 72 recites ("IMPDH") in quotation marks and parentheses in line 5 but without these marks in line 10. See also claim 73-80. Claim 81 recites IMPDH without quotation marks and parentheses. The claims specifically indicate that this acronym is for inosine monophosphate dehydrogenase.

Claims 27-28, 30-31, 33-34, and 85 use the acronym IMPDH but do not recite that the acronym IMPDH means inosine monophosphate dehydrogenase in the claims.

Application/Control Number: 09/678,016

Art Unit: 1647

It does not appear that applicant intends different meanings by reciting IMPDH or ("IMPDH"). However, the claims are inconsistent in their form and use of the acronym. The claims should be amended to be consistent with each other and to avoid confusion. It appears that the claims should not use quotation marks around IMPDH and each independent claim should specifically indicate that this acronym is for inosine monophosphate dehydrogenase. The use of quotation marks does not appear to be used routinely for acronyms in patent claims.

Claims 41, 44, 47 are listed as previously presented claims but contain some of the amendment markings from the amendment submitted on 7/5/05.

Appropriate correction is required.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Art Unit: 1647

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Marianne P. Allen whose telephone number is 571-272-0712. The examiner can normally be reached on Monday-Thursday, 5:30 am - 1:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on 571-272-0961. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Marianne P. Allen
Primary Examiner

7/3/06

Art Unit 1647

mpa